SCHEDULE 13G/A: T. Rowe Price Investment Management Discloses 8.2% Passive Stake in Avanos Medical Inc.
Beneficial Ownership Disclosure
T. Rowe Price Investment Management, Inc. has disclosed a beneficial ownership of 8.2% of Avanos Medical Inc.'s common stock as of March 31, 2025, held in the ordinary course of business.
Summary
- T. Rowe Price Investment Management, Inc. filed an Amendment No. 2 to Schedule 13G regarding its beneficial ownership in Avanos Medical Inc.
- As of March 31, 2025, T. Rowe Price Investment Management, Inc. beneficially owns 3,757,576 shares of Avanos Medical Inc. common stock.
- This ownership represents 8.2% of the total class of Avanos Medical Inc. common stock.
- The reporting person, T. Rowe Price Investment Management, Inc., has sole voting power over 3,735,457 shares and sole dispositive power over 3,757,576 shares.
- The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Avanos Medical Inc.
Sentiment
Score: 7
Explanation: The filing is a routine disclosure of a significant passive stake by a major institutional investor, T. Rowe Price Investment Management, Inc., which is generally viewed as a neutral to slightly positive signal of institutional confidence, without indicating any immediate strategic changes or concerns.
Positives
- A major institutional investor, T. Rowe Price Investment Management, Inc., maintains a significant 8.2% stake in Avanos Medical Inc., which can be interpreted as a continued vote of confidence in the company.
- The filing explicitly states that the shares are held in the ordinary course of business and not for control purposes, indicating a passive, long-term investment perspective from a reputable asset manager.
Risks
- T. Rowe Price Investment Management, Inc. includes a standard legal disclaimer stating that the filing of Schedule 13G should not be construed as an admission of beneficial ownership, which is expressly denied for legal interpretation purposes.
Future Outlook
This Schedule 13G filing does not contain any forward-looking statements or guidance regarding Avanos Medical Inc.'s future performance or T. Rowe Price Investment Management, Inc.'s investment strategy beyond the certification of passive holding.
Management Comments
- T. Rowe Price Investment Management, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
This filing is a routine disclosure of an institutional investor's passive stake and does not provide specific insights into broader industry trends or competitive dynamics within the medical device sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional holdings, potentially reinforcing confidence in the company due to a major asset manager's continued investment.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement (reporting period end date). |
| 05/14/2025 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Avanos Medical Inc, T. Rowe Price Investment Management, Schedule 13G, Common Stock, Institutional Ownership, Investment Adviser, SEC Filing, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.